The study design looks great. Copy the P3 gem/pac combination trial to get very clear efficacy/safety data and regular reporting from open label trial design to inform shareholders.
@reon1 yeah, the wording from that seemed funny to me, but a friend has showed me the P1b results and they are in alignment. Very impressive stuff.
Really all you want to see is definitive PFS/OS/ORR improvements over Soc and any competitors.
The study design looks great. Copy the P3 gem/pac combination...
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
-0.017(13.1%) |
Mkt cap ! $31.60M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 11.5¢ | $322.7K | 2.676M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 135474 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 140642 | 3 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| ATX (ASX) Chart |